

# Ryan D Cassaday

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4035196/publications.pdf>

Version: 2024-02-01

63  
papers

2,367  
citations

304743

22  
h-index

223800

46  
g-index

64  
all docs

64  
docs citations

64  
times ranked

2990  
citing authors

#	ARTICLE	IF	CITATIONS
1	KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. <i>Lancet</i> , The, 2021, 398, 491-502.	13.7	315
2	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. <i>Blood</i> , 2019, 133, 1652-1663.	1.4	277
3	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. <i>Blood</i> , 2019, 133, 1876-1887.	1.4	230
4	Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. <i>Lancet Haematology</i> , the, 2017, 4, e387-e398.	4.6	158
5	Acute Lymphoblastic Leukemia, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1240-1279.	4.9	116
6	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. <i>Blood</i> , 2021, 137, 323-335.	1.4	111
7	Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. <i>American Journal of Hematology</i> , 2019, 94, E209-E213.	4.1	92
8	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. <i>Blood</i> , 2021, 138, 11-22.	1.4	90
9	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2113-2123.	2.0	77
10	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. <i>Blood Advances</i> , 2019, 3, 3062-3069.	5.2	74
11	Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. <i>British Journal of Haematology</i> , 2020, 189, 1119-1126.	2.5	69
12	NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1091-1102.	4.9	67
13	Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. <i>Clinical Cancer Research</i> , 2020, 26, 1247-1257.	7.0	54
14	Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1720-1729.	2.0	53
15	A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 392-397.	0.4	52
16	Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial. <i>Blood</i> , 2016, 128, 1834-1834.	1.4	42
17	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. <i>Blood Advances</i> , 2019, 3, 4228-4237.	5.2	34
18	Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 1680-1680.	1.4	31

#	ARTICLE	IF	CITATIONS
19	Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-“positive relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 905-913.	4.1	30
20	Evaluation of allogeneic transplantation in first or later minimal residual disease “negative remission following adult-inspired therapy for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2109-2118.	1.3	28
21	Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. <i>Lancet Haematology</i> , 2021, 8, e562-e571.	4.6	28
22	Regression of Hodgkin Lymphoma After Discontinuation of a Tumor Necrosis Factor Inhibitor for Crohn's Disease: A Case Report and Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 289-292.	0.4	23
23	Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Age ≥ 60 Years with B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 770-775.	2.0	21
24	Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy. <i>JCO Oncology Practice</i> , 2020, 16, 571-578.	2.9	20
25	Long-Term Outcomes of Patients with Persistent Indolent B-Cell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 281-287.	2.0	19
26	Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020, 4, 3239-3245.	5.2	19
27	Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide,) Tj ETQq1 1 0.784314 rgBT /Overl and Leukemia, 2017, 17, 225-230.	0.4	17
28	Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. <i>Clinical Cancer Research</i> , 2021, 27, 2742-2754.	7.0	16
29	Phase I Study of a CD45-Targeted Antibody-“Radionuclide Conjugate for High-Risk Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 6932-6938.	7.0	15
30	Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 0, Volume 12, 55-79.	2.7	14
31	Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD. <i>American Journal of Hematology</i> , 2018, 93, 546-552.	4.1	13
32	High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 788-797.	2.5	11
33	Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm. <i>Leukemia</i> , 2020, 34, 635-639.	7.2	11
34	Brentuximab vedotin administered to platinum-“refractory, transplant-“na-“ve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. <i>Hematological Oncology</i> , 2015, 33, 187-191.	1.7	10
35	Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. <i>Practical Radiation Oncology</i> , 2020, 10, 44-52.	2.1	10
36	Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. <i>Leukemia and Lymphoma</i> , 2020, 61, 2012-2015.	1.3	10

#	ARTICLE	IF	CITATIONS
37	Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy. <i>Blood</i> , 2018, 132, 94-94.	1.4	10
38	Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2211-2215.	2.0	9
39	Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature Review. <i>Case Reports in Hematology</i> , 2017, 2017, 1-6.	0.4	8
40	Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 282-287.	2.0	8
41	Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 176-181.	0.4	8
42	Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia. <i>Cancer</i> , 2022, 128, 1411-1417.	4.1	8
43	Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 57.e1-57.e8.	1.2	7
44	Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL. <i>Blood</i> , 2021, 138, 3872-3872.	1.4	7
45	Allogeneic hematopoietic cell transplantation in mantle cell lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 165-174.	1.7	6
46	Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?. <i>Current Oncology</i> , 2021, 28, 252-259.	2.2	5
47	Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. <i>Leukemia and Lymphoma</i> , 2018, 59, 363-371.	1.3	4
48	Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1300-1306.	5.0	4
49	Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2021, 62, 234-238.	1.3	4
50	Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e87-e90.	0.4	3
51	Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. <i>British Journal of Haematology</i> , 2020, 191, e77-e81.	2.5	3
52	Pembrolizumab with R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma: Long Term Follow up and Analysis of the Mechanism of Pdl-1 Tumor Expression. <i>Blood</i> , 2020, 136, 13-14.	1.4	3
53	Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 37-45.	5.2	3
54	When a randomized controlled trial is unlikely: Propensity score analysis of blinatumomab in adults with relapsed/refractory Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. <i>Cancer</i> , 2020, 126, 253-255.	4.1	2

#	ARTICLE	IF	CITATIONS
55	Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults. <i>Leukemia and Lymphoma</i> , 2021, 62, 3333-3347.	1.3	2
56	Analysis of Pre-Transplant Therapy with Brentuximab Vedotin for Relapsed/Refractory Hodgkin Lymphoma on Outcomes of Reduced Intensity Conditioned Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015, 126, 4406-4406.	1.4	2
57	Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma. <i>Blood</i> , 2020, 136, 1-2.	1.4	2
58	An unusual case of co-existing classic mantle cell lymphoma and transformed lymphoma with Burkitt-like features with leukemic presentation. <i>Journal of Hematopathology</i> , 2016, 9, 91-99.	0.4	1
59	What Is the Role of Transplantation for Indolent Lymphoma?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 494-500.	3.8	1
60	A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 5502-5502.	1.4	0
61	Real World Utilization and Practice Patterns of Dose-Adjusted EPOCH for Aggressive B-Cell Lymphomas 2005-2015: Impact of Growth Factor Choice and Resultant Achieved Dose Level. <i>Blood</i> , 2016, 128, 3577-3577.	1.4	0
62	Prognostic Parameters in Adults with Acute Lymphoblastic Leukemia at Second Complete Response. <i>Blood</i> , 2016, 128, 1603-1603.	1.4	0
63	Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm. <i>Leukemia</i> , 2022, , .	7.2	0